Open access peer-reviewed Edited Volume

Amyotrophic Lateral Sclerosis - Recent Advances and Therapeutic Challenges

Muralidhar L. Hegde

Houston Methodist Research Institute

Covering

Etiopathologies and Disease subtypes Nucleo-cytoplasmic mislocalization Aggregation Fragmentation Ubiquitination Phosphorylation Transcription Alternative Splicing DNA damage Oxidative genome repair defects Cross-talk of pathologies and neuropathological implications Novel therapeutics

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

Register here

Deadline Extended: Open for Submissions

About the book

The groundbreaking discoveries in 2006 implicating aggregation /fibrillation of the RNA/DNA-binding protein TDP-43 and FUS in amyotrophic lateral sclerosis (ALS) triggered a flurry of research activities towards understanding the neurobiology and pathology of these RNA/DNA binding proteins. Involvement of dozen additional factors including C9ORF72, profilin etc were subsequently reported, however, how these factors trigger neuronal apoptosis still remains unclear, which is a roadblock for developing newer therapeutics. Whether neurotoxicity of RNA/DNA binding proteins in ALS is due to its ‘gain-of-toxicity’ or ‘loss-of-function’ is a key question. While initial research focused on the RNA processing defects, recent studies demonstrated a widespread imbalance in genome damage versus repair, opening avenues for potential DNA repair based therapeutics. Despite significant increase in our understanding of the pathological and biochemical changes in ALS, there is no current cure; available treatments only temporarily slow the disease progression, but do not prevent neuronal death. This underscores the necessity of an overarching approach to unravel the fundamental mechanisms of disease initiation and progression in order to design effective ways develop improved treatment protocols for ALS patients. This book is intended to debate recent advances in our understanding of ALS group of diseases and outline future direction for research activities towards finding a cure for these debilitating brain diseases.

Publishing process

Book initiated and editor appointed

Date completed: August 9th 2019

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: October 29th 2019

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: January 17th 2020

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: March 17th 2020

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Muralidhar L. Hegde

Houston Methodist Research Institute

Dr. Hegde is an Associate Professor at Houston Methodist Research Institute, an affiliate of Cornell University, in Houston, Texas, USA. He also hold adjunct Professor Appointments at Texas A & M University and INDICASAT, Panama. Recently he was awarded a distinguished Visiting Professorship in Tianjin University China under the prestigious Thousands Talents program. Dr. Hegde directs a research program focused on delineating the molecular insights in to the involvement of genome damage/repair responses in human brain pathologies and developing novel mechanism-based treatment strategies for these diseases. Dr. Hegde’s lab utilizes state-of-the art molecular biology/gene editing technologies, human induced pluripotent cell derived neuronal models, as well relevant mice models. Dr. Hegde has published more than 75 research papers in prestigious journals like Nature Communications, Cell Reports, PNAS and JBCs. Dr. Hegde’s research has been continuously funded by National Institute of Health, Muscular Dystrophy Association, ALS Association, Melo Foundation, Alzheimer’s Association etc. He was one of the youngest to be awarded a 2-million dollar NIH R01 grant award at 37 years of age, in 2015. Dr. Hegde has also been a member of NIH and DOD study sections, grant review boards for the Alzheimer’s Association, USA, and grant review boards in Netherlands, France, UK and India. He is deputy chief editor of springer journal Metabolic Brain Diseases, Associate Editor for the Journal of Alzheimer’s Disease and serves on the editorial boards of another half-a-dozen journals. He is invited to review articles routinely for more than 50 international journals.

View profile

Book chapters authored 1

Books edited 0

Introducing your Author Service Manager

Ms. Diana Cop

Ask a question
creativecommons
alpsp
cope
stm
ithenticate
crossref
doi
oaspa

Book will be abstracted and indexed in

googlescholar
worldcat
base
az
openaire